Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms

Medical Clinics of North America

Volumn 94, Issue 4, 2010, Pages 645-664

  Pichler, Werner J ^a,b   Adam, Jaqueline ^a   Daubner, Barbara ^a   Gentinetta, Thomas ^b   Keller, Monika ^b   Yerly, Daniel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ADR AC GmbH   (Switzerland)

Author keywords

Exanthema; Flare up reactions; Gell and Coombs classification; Hapten; Multiple drug hypersensitivity; P i concept; Specific IgE; Type IV reactions

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CARBAMAZEPINE; CEFACLOR; CEPHALOSPORIN; CHIMERIC ANTIBODY; CONTRAST MEDIUM; COTRIMOXAZOLE; DICLOFENAC; HAPTEN; IBUPROFEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LAMOTRIGINE; LEVODOPA; LIDOCAINE; MEFENAMIC ACID; METHYLDOPA; MONOCLONAL ANTIBODY; N,N,N',N' TETRAMETHYL 1,4 PHENYLENEDIAMINE; NEUROMUSCULAR BLOCKING AGENT; PENICILLIN G; PLASMA SUBSTITUTE; PYRAZOLONE; QUINIDINE; QUINOLONE; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ATOPY; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRONCHOSPASM; CARDITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DISEASE CLASSIFICATION; DRESS SYNDROME; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; EDEMA; FACE EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE COMPLEX DEPOSITION; IMMUNOLOGICAL TOLERANCE; LARYNX EDEMA; MACULOPAPULAR RASH; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NEPHRITIS; PATHOPHYSIOLOGY; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PRURITUS; REVIEW; SKIN TEST; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; URINARY TRACT HEMORRHAGE; URTICARIA; VASCULITIS;

ANAPHYLAXIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; HAPTENS; HUMANS; IMMUNOGLOBULIN E; MAJOR HISTOCOMPATIBILITY COMPLEX; NONPRESCRIPTION DRUGS; PRESCRIPTION DRUGS; RECEPTORS, ANTIGEN, T-CELL; RISK FACTORS; T-LYMPHOCYTES;

EID: 77953568669     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.04.003     Document Type: Review

References (52)

1. Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 23 (2000) 483-507
2. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
3. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
4. Bigby M., Jick S., Jick H., et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256 (1986) 3358-3363
5. Hunziker T., Kunzi U.P., Braunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 52 (1997) 388-393
6. Manfredi M., Severino M., Testi S., et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 113 (2004) 155-160
7. Pichler W.J. Drug hypersensitivity: classification and relationship to T cell activation. In: Pichler W.J. (Ed). Drug hypersensitivity (2007), Karger, Basel (Switzerland) 168-189
8. Griem P., Wulferink M., Sachs B., et al. Allergic and autoimmune reactions to xenobiotics: how do they arise?. Immunol Today 19 (1998) 133-141
9. Sanderson J.P., Naisbitt D.J., Farrell J., et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol 178 (2007) 5533-5542
10. Schnyder B., Mauri-Hellweg D., Zanni M., et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 100 (1997) 136-141
11. Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 102 (1998) 1591-1598
12. Pichler W.J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2 (2002) 301-305
13. Pichler W.J. Direct T-cell stimulations by drugs-bypassing the innate immune system. Toxicology 209 (2005) 95-100
14. Sieben S., Kawakubo Y., Al Masaoudi T., et al. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 109 (2002) 1005-1011
15. Naisbitt D.J., Britschgi M., Wong G., et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63 (2003) 732-741
16. Wu Y., Farrell J., Pirmohamed M., et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 119 (2007) 973-981
17. Keller M., Lerch M., Britschgi M., et al. Processing-dependent and -independent pathways for recognition of iodinated contrast media by specific human T cells. Clin Exp Allergy 40 2 (2010) 257-268
18. Burkhart C., Britschgi M., Strasser I., et al. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy 32 (2002) 1635-1643
19. von Greyerz S., Bultemann G., Schnyder K., et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 13 (2001) 877-885
20. Tassaneeyakul W., Jantararoungtong T., Chen P., et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19 (2009) 704-709
21. Man C.B., Kwan P., Baum L., et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48 (2007) 1015-1018
22. Hetherington S., Hughes A.R., Mosteller M., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 (2002) 1121-1122
23. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
24. Chessman D., Kostenko L., Lethborg T., et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28 (2008) 822-832
25. Yang L., Chen J., and He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol 5 (2009) e1000441
26. Yang C.W., Hung S.I., Juo C.G., et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 120 (2007) 870-877
27. Mennicke M., Zawodniak A., Keller M., et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 9 (2009) 2197-2202
28. Coombs P.R., and Gell P.G. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell R.R. (Ed). Clinical aspects of immunology (1968), Oxford University Press, Oxford (UK) 575-596
29. Riezzo I., Bello S., Neri M., et al. Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare. Allergy 65 (2010) 130-131
30. Christensen L.H., Holm J., Lund G., et al. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol 122 (2008) 298-304
31. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction?. Curr Opin Allergy Clin Immunol 4 (2004) 285-290
32. Mertes P.M., Lambert M., Gueant-Rodriguez R.M., et al. Perioperative anaphylaxis. Immunol Allergy Clin North Am 29 (2009) 429-451
33. Brockow K., Romano A., Aberer W., et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 64 (2009) 234-241
34. Florvaag E., and Johansson S.G. The pholcodine story. Immunol Allergy Clin North Am 29 (2009) 419-427
35. Baldo B.A., Fisher M.M., and Pham N.H. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy 39 (2009) 325-344
36. Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 29 (2009) 585-606
37. Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117 (2006) 391-397
38. Pumphrey R.S. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 257 (2004) 116-128 [discussion: 28-32, 57-60, 276-85]
39. Tramer M.R., von Elm E., Loubeyre P., et al. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 333 (2006) 675
40. Aitman T.J., Dong R., Vyse T.J., et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439 (2006) 851-855
41. Stokol T., O'Donnell P., Xiao L., et al. C1q governs deposition of circulating immune complexes and leukocyte Fcgamma receptors mediate subsequent neutrophil recruitment. J Exp Med 200 (2004) 835-846
42. Pichler W.J. Adverse side-effects to biological agents. Allergy 61 (2006) 912-920
43. Nassif A., Bensussan A., Dorothee G., et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 118 (2002) 728-733
44. Schnyder B., Frutig K., Mauri-Hellweg D., et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 28 (1998) 1412-1417
45. Britschgi M., Steiner U.C., Schmid S., et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 107 (2001) 1433-1441
46. Schaerli P., Britschgi M., Keller M., et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 173 (2004) 2151-2158
47. Keller M., Spanou Z., Schaerli P., et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 175 (2005) 7678-7686
48. Beeler A., Engler O., Gerber B.O., et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 117 (2006) 455-462
49. Takahashi R., Kano Y., Yamazaki Y., et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 (2009) 8071-8079
50. Sullivan T. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 83 (1989) 270
51. Gex-Collet C., Helbling A., and Pichler W.J. Multiple drug hypersensitivity-proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. J Investig Allergol Clin Immunol 15 (2005) 293-296
52. Hari Y., Frutig-Schnyder K., Hurni M., et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 31 (2001) 1398-1408